Published in Genes Chromosomes Cancer on July 01, 2006
Epigenetic regulation of phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 gene expression in prostate cancer cells. J Biol Chem (2011) 1.52
Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. PLoS One (2012) 0.88
Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep (2016) 0.84
Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray. BMC Urol (2013) 0.76
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet (2004) 6.85
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2005) 5.31
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum (2005) 4.63
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Mechanisms of androgen-refractory prostate cancer. N Engl J Med (2004) 4.49
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res (2006) 3.83
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science (2006) 3.41
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res (2006) 3.15
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation (2003) 2.99
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med (2009) 2.97
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum (2005) 2.74
Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med (2003) 2.68
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol (2009) 2.64
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
Genetics of adult glioma. Cancer Genet (2012) 2.48
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol (2014) 2.42
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA (2011) 2.28
Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol (2013) 2.28
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
Precision oncology: an overview. J Clin Oncol (2013) 2.10
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One (2008) 2.09
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
Genome-wide association study of glioma and meta-analysis. Hum Genet (2012) 1.96
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst (2011) 1.94
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood (2010) 1.90
Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol (2004) 1.85
Pleiotropic role for MYCN in medulloblastoma. Genes Dev (2010) 1.84
Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J Pain Symptom Manage (2007) 1.83
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res (2005) 1.81
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76
Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2007) 1.67
Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum (2004) 1.67
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer (2004) 1.64
Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration. Arterioscler Thromb Vasc Biol (2007) 1.63
Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol (2013) 1.60
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc (2002) 1.59
A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys (2003) 1.55
Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta (2011) 1.52
Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res (2002) 1.52
Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum (2006) 1.51
Engraftment and tumor formation after allogeneic in utero transplantation of primate embryonic stem cells. Transplantation (2003) 1.51
Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol (2006) 1.50
Promotion of carcinogenesis and oxidative stress by dietary cholesterol in rat prostate. Carcinogenesis (2004) 1.50
Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol (2006) 1.50
p300 in prostate cancer proliferation and progression. Cancer Res (2003) 1.50
How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum (2005) 1.49
Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia. J Cardiovasc Electrophysiol (2004) 1.48
Androgen regulation of gene expression. Adv Cancer Res (2010) 1.47
Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol (2008) 1.46
Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. Am J Clin Pathol (2013) 1.46
Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol (2007) 1.44
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol (2007) 1.44
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol (2002) 1.43
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol (2011) 1.43
Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem (2006) 1.43
Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res (2005) 1.43
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer (2005) 1.40
MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol (2008) 1.40